Table 2 Ongoing clinical studies
From: The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study
Country | Study type | Phase | n | Primary objective |
|---|---|---|---|---|
Nigeria | Sickle cell proguanil vs AS+MQ vs SP+AQ | 1/2 | 270 | Safety and tolerability of bi-monthly intermittent preventive treatment with AS+MQ or sulphadoxine-pyrimethamine + amodiaquine compared to proguanil for prevention of malaria and related complications in patients with sickle cell anaemia |
Amazon Basin | Efficacy | 2/3 | 100 | Evaluate the effectiveness of ASMQ FDC to treat uncomplicated falciparum malaria in the Juruá Valley |
Burkina Faso | Pregnant women | 2/3 | 48 | PK of ASMQ FDC in pregnant women |
Burkina Faso, Ghana, Malawi and Zambia | Pregnant women: ASMQ vs DHA-PQ vs ASAQ vs AL | 3 | 3500 | Efficacy and safety of four ACTs (artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine) in pregnant women with P. falciparum malaria |
Tanzania, Burkina Faso and Kenya | Efficacy, safety and PK in children ASMQ vs AL | 4 | 940 | Efficacy, safety and population pharmacokinetics ASMQ FDC in African children vs artemether-lumefantrine |
Thailand | Pregnant women: ASMQ vs DHA-PQ vs AL | 3 | 1,000 | Randomized trial of three ACT for malaria in pregnancy (DMA) |
Brazil | Efficacy and safety P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ | 3 | 264 | Efficacy and safety for treating P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ |